1
ALL1
Alembic Pharmaceuticals LimitedYear
1
ALL1
2021DEALS // DEV.
1
ALL1
DevelopmentsCountry
1
ALL1
INDIA1
ALL1
InapplicableTherapeutic Area
1
ALL1
Psychiatry/PsychologyStudy Phase
1
ALL1
Approved FDFDeal Type
1
ALL1
InapplicableProduct Type
1
ALL1
Other Small MoleculeDosage Form
1
ALL1
Oral CapsuleLead Product
1
ALL1
Clomipramine HydrochlorideTarget
1
ALL1
Serotonin transporterLead Product(s) : Clomipramine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharma Gets Final Approval from USFDA for OCD Treatment Drug
Details : Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with OCD.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2021
Lead Product(s) : Clomipramine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable